BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 457 participants.
Also called NCT01345656
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 457 participants
- Sponsor
- Registry
-
NCT01345656 -
2011-000301-45
-
- Other papers using this trial's data
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Belgium, Czechia, Denmark, Finland, Germany, Israel, Norway, Poland, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01345656. Randomized; quadruple masking; primary purpose treatment. Start 2011-05-09 (actual); primary completion 2012-05-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
- Acronym
- ARTS
- Condition
- Heart Failure
- Intervention (Drug)
- BAY94-8862
- Intervention (Drug)
- BAY94-8862
- Intervention (Drug)
- BAY94-8862
- Intervention (Drug)
- BAY94-8862
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Spironolactone
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01345656- Content hash
76e33205f528bf9879246a1fefb202815aa9d9ad0300cc18293c6931a6e7d5bf